United Therapeutics Corp (UTHR) Easily Beats Q3 Views; Revs Top $200M
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $487.61 -0.54%
EPS Growth %: -10.1%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -10.1%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics Corp (NASDAQ: UTHR) reported Q3 EPS of $1.65, $0.92 better than the analyst estimate of $0.73. Revenue for the quarter came in at $201.7 million versus the consensus estimate of $194.77 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA accepts United Therapeutics' sNDA for Tyvaso to treat IPF
- FDA accepts United Therapeutics' drug application for IPF treatment
- Genesco (GCO) Tops Q2 EPS by 54c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
